Novothirteen (Catridecacog)

Catridecacog is a recombinant form of activated factor VIII that directly activates factor X on the surface of activated platelets, bypassing the deficient endogenous factor VIII. This restores the intrinsic tenase complex, accelerates thrombin generation, and stabilises clot formation, thereby reducing bleeding in inhibitor‑positive hemophilia A patients.

The dose of Novothirteen is individualized by the prescribing clinician based on the patient’s weight, severity of bleeding, and inhibitor titre. The healthcare professional determines the appropriate amount and frequency, which may differ for prophylaxis, acute bleed treatment, or surgical management.

Data on the use of catridecacog in pregnant or lactating women are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Novothirteen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with bypassing agents such as recombinant activated factor VII (eptacog alfa) or activated prothrombin complex concentrates, catridecacog offers a different mechanism by directly providing activated factor VIII activity. Clinical choice depends on individual response, inhibitor profile, safety considerations, and physician experience.

Novothirteen must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use, and any unused portion should be discarded according to local regulations after the recommended storage period.

Novothirteen is supplied as a sterile lyophilised powder for reconstitution and is administered by intravenous infusion. The reconstituted solution is injected slowly under clinical supervision, with dosing and infusion rate determined by the treating physician based on the clinical situation.

The most serious adverse events include thromboembolic complications such as deep‑vein thrombosis or pulmonary embolism, severe hypersensitivity reactions including anaphylaxis, development of neutralising antibodies that may reduce efficacy, and disseminated intravascular coagulation. Patients should be monitored closely for these signs.

Novothirteen is contraindicated in patients with known hypersensitivity to catridecacog or any of its excipients. It should also be avoided in individuals with a history of severe thrombotic events unless the benefits clearly outweigh the risks, and it is not recommended for use in patients without confirmed factor VIII inhibitors.